GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » Cyclically Adjusted PB Ratio

CNBX Pharmaceuticals (CNBX Pharmaceuticals) Cyclically Adjusted PB Ratio : 0.00 (As of May. 31, 2024)


View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-31), CNBX Pharmaceuticals's current share price is $0.0089. CNBX Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Feb. 2024 was $3.17. CNBX Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for CNBX Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, CNBX Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 61.78. The lowest was 0.01. And the median was 15.46.

CNBX's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.76
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

CNBX Pharmaceuticals's adjusted book value per share data for the three months ended in Feb. 2024 was $-0.076. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.17 for the trailing ten years ended in Feb. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


CNBX Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for CNBX Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals Cyclically Adjusted PB Ratio Chart

CNBX Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.83 15.66 13.63 1.53 0.01

CNBX Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.01 0.01 - -

Competitive Comparison of CNBX Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, CNBX Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CNBX Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



CNBX Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

CNBX Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.0089/3.17
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CNBX Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Feb. 2024 is calculated as:

For example, CNBX Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Feb. 2024 was:

Adj_Book=Book Value per Share/CPI of Feb. 2024 (Change)*Current CPI (Feb. 2024)
=-0.076/130.9299*130.9299
=-0.076

Current CPI (Feb. 2024) = 130.9299.

CNBX Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201405 -0.006 100.373 -0.008
201408 0.048 100.352 0.063
201411 5.271 99.635 6.927
201502 5.239 99.032 6.926
201505 5.048 100.333 6.587
201508 -0.367 100.548 -0.478
201511 0.184 100.135 0.241
201602 -0.465 100.040 -0.609
201605 -0.447 101.355 -0.577
201608 -0.523 101.617 -0.674
201611 -0.242 101.829 -0.311
201702 -0.186 102.779 -0.237
201705 2.918 103.256 3.700
201708 2.950 103.587 3.729
201711 2.431 104.072 3.058
201802 3.235 105.052 4.032
201805 2.618 106.148 3.229
201808 2.612 106.383 3.215
201811 8.257 106.338 10.167
201902 16.311 106.649 20.025
201905 17.241 108.048 20.892
201908 13.155 108.245 15.912
201911 5.375 108.519 6.485
202002 2.800 109.139 3.359
202005 4.529 108.175 5.482
202008 1.568 109.662 1.872
202011 1.115 109.793 1.330
202102 3.357 110.968 3.961
202105 1.963 113.576 2.263
202108 1.458 115.421 1.654
202111 0.506 117.269 0.565
202202 -0.520 119.703 -0.569
202205 -0.954 123.323 -1.013
202208 -1.297 124.958 -1.359
202211 -1.569 125.607 -1.635
202302 -0.911 126.928 -0.940
202305 -0.119 128.314 -0.121
202308 -0.089 129.538 -0.090
202311 -0.074 129.548 -0.075
202402 -0.076 130.930 -0.076

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CNBX Pharmaceuticals  (OTCPK:CNBX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


CNBX Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CNBX Pharmaceuticals (CNBX Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. The company tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds.
Executives
Cannabics Inc. 10 percent owner 108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills director, officer: President, CEO, CFO
North American Mining Corp 10 percent owner 6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford director, officer: Vice-President, Secretary